Page 466 - fbkCardioDiabetes_2017

442 Cardiovascular Outcomes With Antihyperglycemic Therapy:
Past , Present , and Future Impact on Practice

Care. 2013; 36 Suppl 2:S253-8. | Article | PubMed Abstract | PubMed 19. Pfeffer MA, Clagget B, Diaz R, et al. Lixisenatide in patients with type 2
Full Text diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247-
2257. Abstract
3. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth
WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomi- 20. Marso SP, Daniles DH, Brown-Frandsen K, et al. Liraglutide and cardio-
ya T, Patel AA, Paul SK, Travert F and Woodward M. Intensive glucose vascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-
control and macrovascular outcomes in type 2 diabetes. Diabetologia. 322. Abstract
2009; 52:2288-9
21. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular out-
4. Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, Sampaio F, Gama V, comes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-
Leite-Moreira AF, 2014 METformin in DIastolic Dysfunction of MEtabolic 1844. Abstract
syndrome (MET-DIME) trial: rationale and study design: METDIME trial.
Cardiovasc Drugs Ther 28: 191-196 22. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascu-
lar outcomes in patients with type 2 diabetes mellitus. N Engl J Med.
5. Lexis CP, van der Horst IC, Lipsic E, et al, 2012 Metformin in non-diabetic 2013;369:1317-1326. Abstract
patients presenting with ST elevation myocardial infarction: rationale and
design of the glycometabolic intervention as adjunct to primary percuta- 23. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary
neous intervention in ST elevation myocardial infarction (GIPS)-III trial. syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-
Cardiovasc Drugs Ther 26:417-426 1335. Abstract
6. Medical Research Council (MRC) (UK). The Glucose Lowering In Non-di- 24. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on car-
abetic hyperglycaemia Trial (GLINT) - Glucose lowering in those at risk diovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232.
of diabetes. ISRCTN34875079. http://www.isrctn.com/ISRCTN34875079. 25. Zinman B, Wanner C, Lachin JM, et al, 2015 Empagliflozin, cardiovas-
https://njl-admin.nihr.ac.uk/document/download/2006787 cular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:
7. Hemmingsen B, et al. Sulphonylurea monotherapy for patients with type 2117-2128.
2 diabetes mellitus. Cochrane Database Syst Rev. 2013;4:9008. 26. CV Protection in the EMPA-REG OUTCOME Trial: A“Thrifty Substrate” Hy-
pothesis Diabetes Care 2016;39:1108–1114 | DOI: 10.2337/dc16-0330
8. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfony-
lureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 27. Dziuba J, Alperin P, Racketa J, et al, 2014 Modeling effects of SGLT-2 in-
2013;15(10):938–53. hibitor dapagliflozin treatment versus standard diabetes therapy on cardio-
9. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhm- vascular and microvascular outcomes. Diabetes Obes Metab 16: 628-635
ki E, Patel S, Johansen OE and Woerle HJ. Cardiovascular outcome 28. clinicalTrials.gov, Multicenter Trial to Evaluate the Effect of Dapagli-
trials in type 2 diabetes and the sulphonylurea controversy: flozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)
rationale for the active-comparator CAROLINA trial. Diab Vasc NCT01730534 https:// clinicaltrials.gov/ct2/show/NCT01730534 (Ac-
Dis Res. 2013; 10:289-301. | cessed: 9 June 2015)
10. Cardiovascular and Renal Microvascular Outcome Study With 29. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular
Linagliptin in Patients With Type 2 Diabetes Mellitus (CARME- and renal events in type 2 diabetes. N Engl J Med. 2017 Jun 12.
LINA). 2013-2018.
30. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and base-
11. Gerstein HC, Bosch J, Dagenais GR, et al, 2012 Basal insulin and car- line characteristics of the Canagliflozin Cardiovascular Assessment
diovascular and other outcomes in dysglycemia.N Engl J Med 367: 319- Study (CANVAS) — a randomized placebo-controlled trial. Am Heart J.
328. 2016, 2013;166:217-223.e11
12. Cardiovascular and other outcomes postintervention with insulin glargine
and omega-3 fatty acids (ORIGINALE). Diabetes Care 39: 709-716. .
13. Raz I, Wilson PW, Strojek K, et al, 2009 Effects of prandial versus fasting
glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D
trial. Diabetes Care 32: 381-386.
14. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec
versus glargine in type 2 diabetes. N Engl J Med. 2017. doi:10.1056/
NEJMoa1615692 [Epub ahead of print]
15. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE, 2007 Pioglitazone and risk
of cardiovascular events in patients with type 2 diabetes mellitus: a me-
ta-analysis of randomized trials. JAMA - J Am Med Assoc 298 : 1180-1188.
16. Yoshii H, Onuma T, Yamazaki T, et al, 2014 Effects of pioglitazone on
macrovascular events in patients with type 2 diabetes mellitus at high
risk of stroke: the PROFIT-J study. J Atheroscler Thromb 21: 563-573.
17. Lago RM, Singh PP, Nesto RW, 2007 Congestive heart failure and car-
diovascular death in patients with prediabetes and type 2 diabetes given
thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet
370: 1129-1136.
18. Liu J, Wang LN, 2014 Peroxisome proliferator-activated receptor gamma
agonists for preventing recurrent stroke and other vascular events in pa-
tients with stroke or transient ischaemic attack. Cochrane Db Syst Rev
1: CD010693.

GCDC 2017